Adaptation of Mia® (Mammography Intelligence Assessment) to support breast screening programmes to address Covid-19-related breast screening backlog

采用 Mia®（乳房 X 线摄影情报评估）来支持乳房筛查计划，以解决与 Covid-19 相关的乳房筛查积压问题

• 批准号: 56897
• 金额: $ 9.53万
• 依托单位: KHEIRON MEDICAL TECHNOLOGIES LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=56897
• 关键词: Adaptation; Mia; Mammography; Intelligence; Assessment

Due to the Covid-19 outbreak, multiple routine NHS services are on pause, including breast screening programmes. An estimated 3-9 month delay in women being screened will lead to more cancers being missed at the stage where they are easier to treat and immense pressure on an already overburdened system. Our breast cancer screening AI solution Mia (Mammography intelligent assessment) can help solve this impending crisis by automating some aspects of the breast screening programme whilst maintaining current screening performance standards. We have developed a phased approach aligned with the way the human breast radiology readers are brought into the breast screening service and this requires a thorough validation. With breast radiologists, we will validate and test Mia in the pre-commercial period and build trust in the AI. With our NHS partners, we will develop the prospective clinical evidence required for the accelerated adoption of Mia in time to tackle the impending crisis. The output of the project will be an AI solution that can be fast-tracked to reduce the backlogs caused by Covid-19 and give every woman in the UK a better fighting chance against breast cancer.

由于19日疫情，包括乳房筛查计划在内，多次常规NHS服务正在停顿。估计被筛选的女性延迟延迟的3-9个月将导致在已经更容易治疗和对已经负担重大的系统上更容易治疗和巨大压力的阶段中错过更多的癌症。我们的乳腺癌筛查AI解决方案MIA（乳房X线摄影智能评估）可以通过自动化乳房筛查计划的某些方面，同时保持当前筛查性能标准，从而帮助解决这一危机。我们已经开发了一种分阶段的方法，该方法与人类乳房放射学读取器进入乳房筛查服务的方式保持一致，这需要彻底验证。对于乳房放射科医生，我们将在商业前时期验证和测试MIA，并建立对AI的信任。与我们的NHS合作伙伴一起，我们将开发及时加速采用MIA所需的预期临床证据，以应对即将发生的危机。该项目的输出将是一种AI解决方案，可以快速跟踪以减少Covid-19引起的积压，并为英国的每个女性提供更好的对抗乳腺癌的战斗机会。